Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Testosterone for Poor Ovarian Responders: Lessons From Ovarian Physiology
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4378792
Author(s) Polyzos, N. P.; Davis, S. R.; Drakopoulos, P.; Humaidan, P.; De Geyter, C.; Vega, A. G.; Martinez, F.; Evangelou, E.; van de Vijver, A.; Smitz, J.; Tournaye, H.; Barri, P.; Transport Investigators Group, T.
Author(s) at UniBasel de Geyter, Christian M.H.R.
Year 2016
Title Testosterone for Poor Ovarian Responders: Lessons From Ovarian Physiology
Journal Reproductive Sciences
Volume 25
Number 7
Pages / Article-Number 980-982
Keywords infertility; poor ovarian response; poor responders; testosterone
Mesh terms Androgens, therapeutic use; Female; Fertilization in Vitro, methods; Humans; Ovary, physiology; Ovulation Induction; Randomized Controlled Trials as Topic; Sperm Injections, Intracytoplasmic; Testosterone, therapeutic use; Treatment Outcome
Abstract Testosterone, an androgen that directly binds to the androgen receptor, has been shown in previous small randomized controlled trials to increase the reproductive outcomes of poor ovarian responders. In most of these studies, transdermal testosterone in relatively high doses was administered before ovarian stimulation with a duration varying from 5 to 21 days. Nevertheless, the key question to be asked is whether, based on ovarian physiology and testosterone pharmacokinetics, a short course of testosterone administration of more than 10 mg could be expected to have any beneficial effect on reproductive outcome. The rationale for asking this question lies in the existing scientific evidence derived from basic research and animal studies regarding the action of androgens during folliculogenesis, showing that their main effect in follicular development is defined during the earlier developmental stages. In addition, extreme testosterone excess is not only likely to induce adverse events but has also the potential to be ineffective and even detrimental. Thus, evidence from clinical studies is not enough to either "reopen" or "close" the "androgen chapter" in poor responders, mainly because the short administration and the high dose of testosterone is not in line with the ovarian actions of androgens and the presence of androgen receptors during follicular development.
Publisher SAGE PUBLICATIONS INC
ISSN/ISBN 1933-7205
edoc-URL https://edoc.unibas.ch/61632/
Full Text on edoc No
Digital Object Identifier DOI 10.1177/1933719116660849
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/27489169
ISI-Number WOS:000436068600004
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.350 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
07/05/2024